Ask a research question about Schizophrenia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Schizophrenia
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-02-16T20:19:38Z'
category: Psychiatric
parents:
- Psychotic Disorder
- Mental Health Disorder
progression:
- phase: Prodromal
age_range: 15-25
notes: Subtle changes in thoughts, feelings, and behavior
evidence:
- reference: PMID:10225329
reference_title: "From predisposition to psychosis: progression of symptoms in schizophrenia."
supports: SUPPORT
snippet: In adolescence, preschizophrenics exhibit subtle changes in cognition and affect as well as a variety of anomalous subjective experiences (so-called 'basic symptoms'), suggesting 'trait' status of these features.
explanation: This reference indicates that during adolescence, which overlaps with the 15-25 age range, individuals who are preschizophrenic show subtle changes in their thoughts and feelings, aligning with the prodromal phase as described.
- reference: PMID:37027026
reference_title: "Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?"
supports: PARTIAL
snippet: EOP patients had significantly more prodromal symptoms with a higher frequency of trouble with thinking, avolition and hallucinations than AOP patients.
explanation: This study supports the presence of subtle changes in thinking and behavior during the prodromal phase in early-onset psychosis, which includes patients younger than 18, blending into the 15-25 age range.
- phase: Onset
age_range: 16-30
notes: First episode of psychosis
evidence:
- reference: PMID:7654792
reference_title: "Epidemiology of early-onset schizophrenia."
supports: PARTIAL
snippet: Early-onset schizophrenias (< or = 20 years) were compared with a medium-onset group (21 - < 35 years) and a late-onset group (35 - < 60 years) with regard to age and type of onset, early symptom-related course, social development and social course.
explanation: The study provides information about the age of onset and early course of schizophrenia that falls within the 16-30 age range but does not specifically address the entire age range spectrum for the onset of the first episode of psychosis.
- reference: PMID:20021319
reference_title: "Progressive structural brain changes in schizophrenia."
supports: PARTIAL
snippet: There are progressive frontal changes in males with adolescent-onset psychosis... Ultra high-risk patients who subsequently develop psychosis and first-episode psychosis patients develop significant grey matter reduction in the planum polare, planum temporale and caudal region; a progressive process in the superior temporal gyrus may precede the first expression of florid psychosis.
explanation: This literature provides evidence about the progression of schizophrenia, particularly related to brain changes, within the stated age range of 16-30 years during the onset phase of the first episode of psychosis.
- reference: PMID:10225329
reference_title: "From predisposition to psychosis: progression of symptoms in schizophrenia."
supports: PARTIAL
snippet: Prodromal symptoms occur in a substantial proportion of preschizophrenics, followed by a short prepsychotic phase with the crystallization of a psychotic syndrome.
explanation: This reference supports the progression of schizophrenia during the onset phase and includes the age group that aligns with the 16-30 age range.
- reference: PMID:26467909
reference_title: "Predictors of Relapse and Functioning in First-Episode Psychosis: A Two-Year Follow-Up Study."
supports: PARTIAL
snippet: Patients with first-episode psychosis were found to have high relapse rates during the first years after illness onset.
explanation: While discussing the progression of symptoms and outcomes following the first episode of psychosis, this study does not focus specifically on the age range of 16-30 years.
- phase: Chronic
notes: Long-term management of symptoms and functioning
evidence:
- reference: PMID:9789265
reference_title: "[Long-term treatment of chronic schizophrenia]."
supports: SUPPORT
snippet: Long-term treatment of patients with chronic schizophrenias requires integration of many therapeutic approaches, co-operation of several professions, and regard for the views of patients and relatives.
explanation: The excerpt supports the idea that managing symptoms and functioning in chronic schizophrenia requires long-term management.
- reference: PMID:23172002
reference_title: "The myth of schizophrenia as a progressive brain disease."
supports: PARTIAL
snippet: The evidence shows that although approximately 25% of people with schizophrenia have a poor long-term outcome, few of these show the incremental loss of function that is characteristic of neurodegenerative illnesses.
explanation: This statement supports the idea that while a subset of patients experience poor long-term outcomes, most do not have progressive deterioration like in neurodegenerative diseases.
- reference: PMID:10082190
reference_title: "Criteria defining refractory schizophrenia."
supports: SUPPORT
snippet: The criteria proposed necessitate (i) diagnosis of schizophrenia by standard operational criteria, (ii) continuous hospitalization for at least the past 2 years, (iii) a level of psychosocial functioning of < or = 40 as measured by the Global Assessment Scale, and (iv) an intensity score of 'marked' or 'severe' on at least three of the six Manchester Scale items.
explanation: The criteria for refractory schizophrenia include long-term management indicating that managing symptoms and functioning over time is essential.
- reference: PMID:26168930
reference_title: "Investigating the long-term course of schizophrenia by sequence analysis."
supports: SUPPORT
snippet: A cluster analysis performed on the resulting similarity matrix yielded two main groups (a 'improving' and a 'chronic' group), which comprised a total of six different types of illness course.
explanation: The study's finding of an 'improving' and 'chronic' group supports that managing symptoms and functioning is a significant aspect for those in the chronic phase.
prevalence:
- population: global
percentage: 0.3-0.7
notes: 'male_to_female_ratio: 1.4:1'
evidence:
- reference: PMID:18480098
reference_title: "Schizophrenia: a concise overview of incidence, prevalence, and mortality."
supports: PARTIAL
snippet: The rate ratio for males:females was 1.4:1. Prevalence estimates also show prominent variation.
explanation: While the male to female ratio of incidence is reported as 1.4:1, the abstract does not provide exact figures on the percentage of the population affected except that there is prominent variation. Therefore, the part of the statement with the percentage is not directly supported by this source.
pathophysiology:
- name: Dysregulation of Dopamine Neurotransmission
synonyms:
- Dopamine Hypothesis
description: Imbalance in dopamine transmission in the brain, particularly in the mesolimbic and mesocortical pathways.
biological_processes:
- preferred_term: dopamine secretion
term:
id: GO:0014046
label: dopamine secretion
locations:
- preferred_term: striatum
downstream:
- target: Psychotic Symptoms
description: Striatal dopamine dysregulation causes abnormal salience attribution resulting in psychotic symptoms.
evidence:
- reference: PMID:35390609
reference_title: "Schizophrenia: A developmental disorder with a risk of non-specific but avoidable decline."
supports: SUPPORT
snippet: Striatal dopamine dysregulation follows, causing abnormal salience and resultant psychotic symptoms.
explanation: This 2022 review describes how dopamine dysregulation in the striatum creates abnormal salience attribution which directly results in the psychotic symptoms characteristic of schizophrenia.
evidence:
- reference: PMID:27206569
reference_title: "Pathway-Specific Dopamine Abnormalities in Schizophrenia."
supports: PARTIAL
snippet: Findings have converged to suggest early dysregulation in the striatum, especially in the rostral caudate, manifesting as excess synthesis and release. Recent data showed deficit extending to most cortical regions and even to other extrastriatal subcortical regions not previously considered to be 'hypodopaminergic' in schizophrenia.
explanation: While the literature supports dopamine dysregulation in various brain regions, it does not specifically emphasize the mesolimbic and mesocortical pathways alone.
- reference: PMID:24986384
reference_title: "A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic)."
supports: NO_EVIDENCE
snippet: 'A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).'
explanation: The abstract does not provide specific information supporting the imbalance of dopamine transmission specifically in the mesolimbic and mesocortical pathways as described in the statement.
- reference: PMID:1981107
reference_title: "Schizophrenia: a subcortical neurotransmitter imbalance syndrome?"
supports: NO_EVIDENCE
snippet: This article discusses the possibility that a deficient activity within the cortico-striatal glutamatergic pathway is an important pathophysiological component in some cases of schizophrenia and that glutamatergic agonists may prove beneficial in this disorder.
explanation: The study focuses on glutamate dysregulation rather than dopamine transmission dysregulation in mesolimbic and mesocortical pathways.
- reference: PMID:24128684
reference_title: "Is schizophrenia a dopamine supersensitivity psychotic reaction?"
supports: PARTIAL
snippet: This clinical picture is generally associated with supersensitivity to dopamine, and activates dopamine neurotransmission that is usually alleviated or blocked by drugs that block dopamine D2 receptors.
explanation: There is an implication of dopamine dysregulation, but the specifics of mesolimbic and mesocortical pathways are not confirmed.
- name: Abnormality of Glutamergic Signaling
synonyms:
- Glutamate Hypothesis
description: Dysfunction in glutamate neurotransmission, impacting synaptic plasticity and brain circuit function.
cell_types:
- preferred_term: parvalbumin-positive interneuron
description: NMDA hypofunction on parvalbumin interneurons leads to cortical disinhibition.
term:
id: CL:0000099
label: interneuron
biological_processes:
- preferred_term: synaptic transmission, glutamatergic
term:
id: GO:0035249
label: synaptic transmission, glutamatergic
locations:
- preferred_term: prefrontal cortex
term:
id: UBERON:0000451
label: prefrontal cortex
- preferred_term: hippocampus
term:
id: UBERON:0001954
label: Ammon's horn
evidence:
- reference: PMID:11532718
reference_title: "The emerging role of glutamate in the pathophysiology and treatment of schizophrenia."
supports: SUPPORT
snippet: Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia.
explanation: The literature specifically states that glutamatergic neurotransmission dysfunction is associated with the pathophysiology of schizophrenia, supporting the provided statement.
- reference: PMID:28754595
reference_title: "Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features."
supports: SUPPORT
snippet: Accumulating evidence suggests that synaptic plasticity is impaired in schizophrenia. Given the role of synaptic plasticity in learning, memory, and neural circuit maturation, impaired plasticity may underlie many features of the schizophrenia syndrome.
explanation: The literature discusses the impairment of synaptic plasticity in schizophrenia and its interaction with brain maturation, aligning with the statement.
- reference: PMID:29954475
reference_title: "Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate."
supports: SUPPORT
snippet: Psychosis is now widely hypothesized to involve neural networks beyond the classical dopaminergic mesolimbic pathway, including serotonin and glutamate systems as well.
explanation: This reference supports the involvement of glutamatergic systems in schizophrenia, reinforcing the statement.
- reference: PMID:22351070
reference_title: "Synaptic dysfunction in schizophrenia."
supports: SUPPORT
snippet: Schizophrenia is believed to result from problems during neural development that lead to improper function of synaptic transmission and plasticity, and in agreement, many of the susceptibility genes encode proteins critical for neural development.
explanation: The literature supports the idea that schizophrenia impacts synaptic transmission and plasticity, specifically implicating glutamatergic, GABAergic, dopaminergic, and cholinergic synapses.
- name: Abnormality of GABAergic Signaling
synonyms:
- GABAergic Dysfunction
description: Dysfunction in GABAergic inhibitory neurotransmission, contributing to excitatory/inhibitory (E/I) imbalance in cortical circuits.
cell_types:
- preferred_term: parvalbumin-positive interneuron
description: Parvalbumin-positive GABAergic interneurons show reduced function, leading to cortical disinhibition.
term:
id: CL:0000099
label: interneuron
biological_processes:
- preferred_term: synaptic transmission, GABAergic
term:
id: GO:0051932
label: synaptic transmission, GABAergic
locations:
- preferred_term: prefrontal cortex
term:
id: UBERON:0000451
label: prefrontal cortex
evidence:
- reference: PMID:10372507
reference_title: "GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses."
supports: SUPPORT
snippet: At the cellular level, gamma-aminobutyric acid (GABA)-ergic interneurons are a common feature in psychotic states... and are themselves synchronised by the ascending dopamine and serotonin innervations.
explanation: The literature highlights that GABAergic interneurons play a significant role in the cellular characteristics found in psychotic states, including schizophrenia.
- reference: PMID:22308256
reference_title: "[Biological study in schizophrenia]."
supports: SUPPORT
snippet: Disturbances in glutamate and GABAergic neurotransmission may underlie the pathophysiology of schizophrenia.
explanation: This reference directly states that disturbances in GABAergic neurotransmission may underlie the pathophysiology of schizophrenia.
- reference: PMID:34584230
reference_title: "Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of (1)H-magnetic resonance spectroscopy studies."
supports: SUPPORT
snippet: Reduced GABA levels indicate that the disruption of excitatory/inhibitory balance may be related to the pathophysiology of schizophrenia-spectrum disorders.
explanation: This meta-analysis supports the idea that reduced GABA levels and thus GABAergic dysfunction are related to the pathophysiology of schizophrenia.
- reference: PMID:25432637
reference_title: "GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism."
supports: SUPPORT
snippet: Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain. GABAergic receptor abnormalities have been documented in several major psychiatric disorders including schizophrenia.
explanation: The abnormalities in GABAergic receptors in schizophrenia support the idea of GABAergic signaling abnormalities being part of the disorder’s pathophysiology.
- reference: PMID:22351070
reference_title: "Synaptic dysfunction in schizophrenia."
supports: SUPPORT
snippet: Here, we will review evidence for altered neurotransmission at ... GABAergic ... synapses in schizophrenia...
explanation: This article reviews evidence for altered GABAergic neurotransmission in schizophrenia, supporting the stated claim.
- name: Complement-Mediated Excessive Synaptic Pruning
description: Excessive elimination of synapses by microglia via complement component C4A and CR3 pathways during adolescent brain development.
cell_types:
- preferred_term: microglial cell
description: Microglia eliminate synapses tagged by complement components during critical developmental periods.
term:
id: CL:0000129
label: microglial cell
biological_processes:
- preferred_term: complement activation
term:
id: GO:0006956
label: complement activation
- preferred_term: synapse pruning
term:
id: GO:0098883
label: synapse pruning
locations:
- preferred_term: prefrontal cortex
term:
id: UBERON:0000451
label: prefrontal cortex
- preferred_term: hippocampus
term:
id: UBERON:0001954
label: Ammon's horn
- name: Oligodendrocyte and Myelin Dysfunction
description: Abnormalities in oligodendrocytes and myelin sheaths leading to white matter changes and network dysconnectivity across brain regions.
cell_types:
- preferred_term: oligodendrocyte
description: Oligodendrocyte dysfunction contributes to impaired myelination and dysconnectivity.
term:
id: CL:0000128
label: oligodendrocyte
biological_processes:
- preferred_term: myelination
term:
id: GO:0042552
label: myelination
locations:
- preferred_term: prefrontal cortex
term:
id: UBERON:0000451
label: prefrontal cortex
- preferred_term: hippocampus
term:
id: UBERON:0001954
label: Ammon's horn
- name: Mitochondrial Dysfunction and Oxidative Stress
description: Bioenergetic deficits including complex I inhibition, decreased glutathione, increased lactate, and oxidative/nitrosative stress creating a feed-forward cycle with neuroinflammation.
biological_processes:
- preferred_term: oxidative phosphorylation
term:
id: GO:0006119
label: oxidative phosphorylation
- preferred_term: cellular response to oxidative stress
term:
id: GO:0034599
label: cellular response to oxidative stress
locations:
- preferred_term: prefrontal cortex
term:
id: UBERON:0000451
label: prefrontal cortex
- name: Blood-Brain Barrier Dysfunction
description: Increased BBB permeability with elevated CSF albumin and immunoglobulins, involving dysfunction of endothelial cells, pericytes, and astrocytes in the neurovascular unit.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
- preferred_term: astrocyte
term:
id: CL:0000127
label: astrocyte
locations:
- preferred_term: blood-brain barrier
phenotypes:
- category: Psychiatric
name: Hallucinations
frequency: FREQUENT
diagnostic: true
notes: Often auditory in nature, such as hearing voices. Can also be visual, tactile, or olfactory.
evidence:
- reference: PMID:28437056
reference_title: "Psychotic and Bipolar Disorders: Schizophrenia."
supports: SUPPORT
snippet: 'Schizophrenia symptoms fall into six common symptom clusters: delusions and hallucinations, disorganization of speech, cognitive dysfunction, negative symptoms, affective symptoms, and motor system abnormalities.'
explanation: Delusions and hallucinations are recognized as common symptom clusters in schizophrenia, supporting the statement that hallucinations are frequent and a part of the psychiatric diagnostic category.
- reference: PMID:25773224
reference_title: "Ophthalmology issues in schizophrenia."
supports: PARTIAL
snippet: Schizophrenia is a complex mental disorder associated with not only cognitive dysfunctions, such as memory and attention deficits, but also changes in basic sensory processing.
explanation: This supports the note that hallucinations in schizophrenia can be auditory, visual, tactile, or olfactory in nature, indicating changes in sensory processing.
- reference: PMID:21545448
reference_title: "Clinical correlates of olfactory hallucinations in schizophrenia."
supports: SUPPORT
snippet: Prevalence of OHs and hallucinations in other modalities differed according to the WHO-10 international centre. Across centres, OHs were present in 13% of the WHO-10 dataset, similar to the 17% prevalence rate in the SAPS/SANS dataset.
explanation: This supports the claim that olfactory hallucinations are among the types of hallucinations experienced by schizophrenic patients, although less frequent than auditory hallucinations.
- reference: PMID:35383683
reference_title: "Auditory Verbal Hallucinations in Schizophrenia, Part II: Phenomenological Qualities and Evolution."
supports: PARTIAL
snippet: We found that a substantial proportion of patients could not clearly distinguish between thinking and hallucinating. The emotional tone of the voices increased in negativity.
explanation: This supports the auditory nature of hallucinations (hearing voices) but does not provide comprehensive support for visual, tactile, or olfactory hallucinations.
phenotype_term:
preferred_term: Hallucinations
term:
id: HP:0000738
label: Hallucinations
- category: Psychiatric
name: Delusions
frequency: FREQUENT
diagnostic: true
notes: False beliefs, often paranoid or grandiose in nature. Resistant to contradictory evidence.
evidence:
- reference: PMID:33485408
reference_title: "Delusions beyond beliefs: a critical overview of diagnostic, aetiological, and therapeutic schizophrenia research from a clinical-phenomenological perspective."
supports: PARTIAL
snippet: Delusions are commonly conceived as false beliefs that are held with certainty and which cannot be corrected. This conception of delusion has been influential throughout the history of psychiatry and continues to inform how delusions are approached in clinical practice and in contemporary schizophrenia research.
explanation: The literature describes delusions as false beliefs that are resistant to contradictory evidence, which aligns with the statement's note that delusions in schizophrenia are often paranoid or grandiose in nature.
- reference: PMID:949230
reference_title: "The Capgras phenomenon."
supports: PARTIAL
snippet: The underlying diagnosis of Capgras delusion is not found to be exclusively paranoid schizophrenia, nor is the sex exclusively female, as once was believed.
explanation: While Capgras delusion may involve delusions, the reference suggests that these delusions are not exclusively found in paranoid schizophrenia. This partially supports the statement but adds another layer of complexity.
- reference: PMID:29151090
reference_title: "De Clérambault Syndrome, Othello Syndrome, Folie à Deux and Variants."
supports: NO_EVIDENCE
snippet: Non-bizarre delusion, defined as a false belief possible although highly unlikely, is the main manifestation of delusional disorders, previously known as paranoia.
explanation: The description of non-bizarre delusions aligns with the statement that delusions, which are false beliefs, are a frequent psychiatric diagnostic category in schizophrenia.
- reference: PMID:24677735
reference_title: "Unravelling offending in schizophrenia: factors characterising subgroups of offenders."
supports: PARTIAL
snippet: Persecutory and/or grandiose delusions were more strongly associated with each offender group compared with non-offenders, most so with late first offenders.
explanation: This reference supports the statement as it mentions paranoid and grandiose delusions being prevalent in patients with schizophrenia.
phenotype_term:
preferred_term: Delusions
term:
id: HP:0000746
label: Delusion
- category: Cognitive
name: Disorganized Thinking
frequency: FREQUENT
diagnostic: true
notes: Impaired logical thought process and communication. May manifest as loose associations or incoherent speech.
evidence:
- reference: PMID:30488088
reference_title: "[Impairments of language and communication in schizophrenia]."
supports: SUPPORT
snippet: Disorganized speech is one of the key symptoms of schizophrenia. This article provides an overview of those areas of speech and communication impaired in patients with schizophrenia.
explanation: Disorganized thinking is closely related to disorganized speech, which is highlighted as a frequent impairment in schizophrenia.
- reference: PMID:2084786
reference_title: "Studies of the course of schizophasia."
supports: SUPPORT
snippet: The course of psychoses of schizophrenic type follows rules which are still not adequately understood. It is, however, clear that certain symptoms appear mostly early, others only late... we studied 44 final phase patients whose main symptom was disordered thinking of the schizophasic type.
explanation: The study highlights disordered thinking (a form of cognitive impairment) as a main symptom in later stages of schizophrenia.
- reference: PMID:37040138
reference_title: "Deficits in Analytic and Common-Sense Reasoning in Schizophrenia."
supports: SUPPORT
snippet: Patients with schizophrenia were impaired in both analytic and common-sense thinking.
explanation: Impaired logical thought processes and communication, which might manifest as loose associations or incoherent speech, align with the cognitive phenotype of disorganized thinking.
- reference: PMID:35752547
reference_title: "Syntactic complexity of spoken language in the diagnosis of schizophrenia: A probabilistic Bayes network model."
supports: SUPPORT
snippet: We conclude that an early drift towards linguistic disorganization/impoverishment of clause complexity-at the granular level of nominal subject per clause-is a distinctive feature of schizophrenia that decreases longitudinally, thus differentiating schizophrenia from other psychotic illnesses with shared phenomenology.
explanation: Linguistic disorganization and impoverishment of clause complexity are reflective of impaired logical thought process and communication, supporting the cognitive phenotype of disorganized thinking.
- reference: PMID:17477206
reference_title: "Delusional thinking and cognitive disorder."
supports: PARTIAL
snippet: The data of interest are (a) the failure to find evidence of cognitive impairment in diagnosed paranoid patients...
explanation: While the study discusses delusional thinking with little evidence of cognitive impairment in paranoid patients, it does suggest that cognitive mechanisms in schizophrenia may differ, providing partial support to the cognitive phenotype.
- category: Occupational
name: Social Withdrawal
frequency: FREQUENT
notes: Reduction in social interactions and engagement. Can lead to isolation and difficulty maintaining relationships.
evidence:
- reference: PMID:31390645
reference_title: "Social Life in the Schizophrenia Spectrum: A Phenomenological Study of Five Patients."
supports: SUPPORT
snippet: A 'positively withdrawn' position characterizes a wider group of patients than originally reported. Further, we identified a preference for partaking in social activities in particular circumstances with clearly circumscribed goals or social roles and rules.
explanation: The study indicates that social withdrawal is a significant aspect of schizophrenia and is frequently observed among patients.
- reference: PMID:35102081
reference_title: "Social withdrawal and neurocognitive correlates in schizophrenia."
supports: SUPPORT
snippet: Social withdrawal was measured by a specific item of the Heinrichs-Carpenter Quality of Life Scale. Social withdrawal was associated with a lower score in the neurocognitive composite score and in 'Verbal memory,' 'Processing speed' and 'Working memory' scores.
explanation: The study confirms the association between social withdrawal and various neurocognitive deficits in schizophrenia, supporting its frequent occurrence.
- reference: PMID:11103877
reference_title: "Animal models for the negative symptoms of schizophrenia."
supports: SUPPORT
snippet: Negative symptoms encompass, among others, anhedonia, flat affect, avolition and social withdrawal.
explanation: The review details social withdrawal as a prominent negative symptom in schizophrenia, further corroborating its frequent occurrence.
- reference: PMID:28637195
reference_title: "Social Disconnection in Schizophrenia and the General Community."
supports: SUPPORT
snippet: Social disability is a defining characteristic of schizophrenia... One component, social disconnection, occurs extensively... Social disconnection is an objective, long-standing lack of social/family relationships and minimal participation in social activities.
explanation: The paper discusses social withdrawal as a central component of social disability in schizophrenia.
- category: Mood
name: Flat Affect
frequency: FREQUENT
notes: Reduced expression of emotions. May appear unresponsive or lacking emotional depth.
evidence:
- reference: PMID:16452608
reference_title: "Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures."
supports: SUPPORT
snippet: Impaired emotional functioning in schizophrenia is a prominent clinical feature that manifests primarily as flat affect... Flat affect was more common in men and was associated with poorer premorbid adjustment, worse current quality of life, and worse outcome at 1-year follow-up.
explanation: The study provides evidence that flat affect is a frequent and prominent clinical feature of schizophrenia, which aligns with the statement.
- reference: PMID:23846857
reference_title: "Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP)."
supports: PARTIAL
snippet: Schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations.
explanation: The reference suggests that flat affect, which is an emotional deficit, is part of the clinical phenotype of schizophrenia.
- reference: PMID:31839552
reference_title: "Voice patterns in schizophrenia: A systematic review and Bayesian meta-analysis."
supports: SUPPORT
snippet: Voice atypicalities have been a characteristic feature of schizophrenia ... They are often associated with core negative symptoms such as flat affect and alogia ... This suggests that voice atypicalities may represent a marker of clinical features and social functioning in schizophrenia.
explanation: The study mentions flat affect as one of the core negative symptoms of schizophrenia, supporting its frequent occurrence within the schizophrenia phenotype.
- reference: PMID:11103877
reference_title: "Animal models for the negative symptoms of schizophrenia."
supports: SUPPORT
snippet: In schizophrenia, negative symptoms encompass, among others, anhedonia, flat affect, avolition, and social withdrawal.
explanation: This review states that flat affect is one of the negative symptoms associated with schizophrenia, supporting the frequent occurrence.
- reference: PMID:28242515
reference_title: "Emotional word usage in groups at risk for schizophrenia-spectrum disorders: An objective investigation of attention to emotion."
supports: PARTIAL
snippet: Both extreme levels of social anhedonia (SocAnh) and extreme levels of perceptual aberration/magical ideation (PerMag) indicate increased risk for schizophrenia-spectrum disorders and are associated with emotional deficits.
explanation: The study discusses emotional deficits in groups at risk for schizophrenia, implying the presence of flat affect as a frequent feature.
- reference: PMID:11122987
reference_title: "Defining the schizophrenia phenotype."
supports: PARTIAL
snippet: The schizophrenia phenotype has been traditionally defined by chronic psychosis and functional deterioration ... Subtle clinical signs and symptoms, cognitive impairment particularly in attention and memory, and neurophysiologic deficits such as in sensory gating and smooth-pursuit eye movements all define aspects of the schizophrenia phenotype.
explanation: Even though flat affect is not explicitly mentioned, the reference discusses emotional and cognitive impairments, supporting the statement indirectly.
- category: Cognitive
name: Working Memory Deficits
frequency: COMMON
notes: Difficulties in short-term information storage and manipulation.
evidence:
- reference: PMID:36252418
reference_title: "Evidence that a working memory cognitive phenotype within schizophrenia has a unique underlying biology."
supports: SUPPORT
snippet: Our data gives preliminary support to the hypotheses that there is a working memory deficit phenotype within the syndrome of schizophrenia with has a biological underpinning.
explanation: Evidence suggests there is a working memory deficit phenotype within schizophrenia.
- reference: PMID:30104335
reference_title: "Posterior Parietal Cortex Dysfunction Is Central to Working Memory Storage and Broad Cognitive Deficits in Schizophrenia."
supports: SUPPORT
snippet: PFC dysfunction is widely believed to underlie working memory (WM) deficits in people with schizophrenia (PSZ)...These results indicate that PPC dysfunction is central to WM storage deficits in PSZ and may play a key role in the broad cognitive deficits associated with schizophrenia.
explanation: The literature highlights WM deficits as a central part of cognitive impairment in schizophrenia.
- reference: PMID:20053864
reference_title: "Iconic decay in schizophrenia."
supports: SUPPORT
snippet: Working memory impairment is considered a core deficit in schizophrenia.
explanation: The study directly supports the existence of working memory deficits as a core phenotype in schizophrenia.
- reference: PMID:19328655
reference_title: "Schizophrenia, \"just the facts\" 4. Clinical features and conceptualization."
supports: PARTIAL
snippet: It is characterized by an admixture of positive, negative, cognitive, mood, and motor symptoms whose severity varies across patients and through the course of the illness.
explanation: Although the snippet is general, cognitive deficits typically encompass working memory as part of the broader impairment in schizophrenia.
- category: Behavioral
name: Catatonia
frequency: OCCASIONAL
notes: Abnormal motor behavior, ranging from excessive movement to immobility.
evidence:
- reference: PMID:11478416
reference_title: "Catatonia: syndrome or schizophrenia subtype? Recognition and treatment."
supports: PARTIAL
snippet: Catatonia is a parallel behavior phenomenon to delusions (in thought) and delirium (in cognition).
explanation: The reference suggests catatonia is associated with schizophrenia but does not specify the frequency of this phenotype.
- reference: PMID:34785041
reference_title: "Low physical activity is associated with two hypokinetic motor abnormalities in psychosis."
supports: PARTIAL
snippet: Lower activity levels correlated with increased age and severity of catatonia and parkinsonism. The 22 patients with catatonia had lower activity as well as higher scores on parkinsonism, involuntary movements, and negative symptoms compared to the 30 patients without catatonia.
explanation: The study indicates catatonia is present in some patients with schizophrenia but does not specify its frequency.
- reference: PMID:22814247
reference_title: "Motor symptoms and schizophrenia."
supports: PARTIAL
snippet: Classical schizophrenia literature reports motor symptoms as characteristic of the disorder... This review of the literature supports the idea that motor symptoms are closely related to the neurodevelopmental disturbances of schizophrenia and a distinct syndromal dimension with its own pathophysiology.
explanation: The literature suggests catatonia, as a motor symptom, is a recognized aspect of schizophrenia.
- reference: PMID:30177576
reference_title: "[Symptoms Specific to Schizophrenia]."
supports: NO_EVIDENCE
snippet: Symptoms specific to schizophrenia include self-disturbances, delusional perception and loosening of associations.
explanation: Though this reference focus on other symptoms, it indirectly supports catatonia as one of the reported motor symptoms in schizophrenia spectrum conditions.
- reference: PMID:37655417
reference_title: "[Periodic catatonia in schizophrenia spectrum disorders]."
supports: PARTIAL
snippet: 'Three forms of periodic catatonia have been identified: hypokinetic, parakinetic, multikinetic.'
explanation: The study supports the presence of catatonia in schizophrenia but does not clarify the frequency.
- reference: PMID:20587767
reference_title: "Clozapine-withdrawal catatonia."
supports: NO_EVIDENCE
snippet: Case reports in which abrupt clozapine discontinuation led to a return of psychosis, autonomic instability, or catatonia.
explanation: This case study does not provide evidence about the general frequency of catatonia in schizophrenia.
biochemical:
- name: Dopamine Metabolites
presence: Elevated
context: Observed in cerebrospinal fluid and postmortem brain analysis.
evidence:
- reference: PMID:39348
reference_title: "Biochemistry and the schizophrenias."
supports: NO_EVIDENCE
snippet: Elevated levels [of dimethyltryptamine] are found in some cases of schizophrenia and of liver disease.
explanation: The study mentions elevated levels of the dopamine metabolite dimethyltryptamine in cerebrospinal fluid of schizophrenic patients.
- reference: PMID:37271040
reference_title: "CSF dopamine is elevated in first-episode psychosis and associates to symptom severity and cognitive performance."
supports: PARTIAL
snippet: CSF dopamine was reliably detected in 50% of healthy controls and in 65% of first-episode psychosis subjects and significantly higher in first-episode psychosis subjects compared to age-matched healthy controls.
explanation: This study shows increased cerebrospinal fluid dopamine levels, which are related to dopamine metabolism, in first-episode psychosis subjects, supporting elevated dopamine metabolites in CSF in schizophrenia.
- reference: PMID:9278185
reference_title: "Cortical dopamine in schizophrenia: strategies for postmortem studies."
supports: NO_EVIDENCE
snippet: The application of this strategy, and its value in overcoming some of the potential pitfalls of postmortem studies, is demonstrated in a series of investigations designed to test the hypothesis that dopamine neurotransmission is impaired in the entorhinal cortex in schizophrenia.
explanation: While it discusses postmortem brain analysis and dopamine dysfunction in schizophrenia, it does not specifically state elevated dopamine metabolites.
- reference: PMID:18366307
reference_title: "Cerebrospinal fluid: identification of diagnostic markers for schizophrenia."
supports: NO_EVIDENCE
snippet: Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application.
explanation: The study discusses the difficulty in identifying reliable diagnostic markers in the cerebrospinal fluid of schizophrenia patients without specifically mentioning elevated dopamine metabolites.
- name: Glutamate Levels
presence: Elevated
context: Observed in cerebrospinal fluid and postmortem brain analysis.
evidence:
- reference: PMID:18366307
reference_title: "Cerebrospinal fluid: identification of diagnostic markers for schizophrenia."
supports: NO_EVIDENCE
snippet: Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application.
explanation: The study discusses the search for diagnostic markers in CSF but does not provide specific evidence for elevated glutamate levels.
- reference: PMID:11684348
reference_title: "Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia."
supports: NO_EVIDENCE
snippet: Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl D-aspartate-receptor.
explanation: This study focuses on the elevated levels of kynurenic acid, not directly on glutamate levels.
- reference: PMID:20846490
reference_title: "Alterations in dopamine and glutamate neurotransmission in tetrahydrobiopterin deficient spr-/- mice: relevance to schizophrenia."
supports: PARTIAL
snippet: Accordingly, it is possible that abnormalities in the biochemical cascades regulated by BH(4) may alter DA, 5-HT and Glu neurotransmission, and consequently contribute to the pathophysiology of different neuropsychiatric diseases including schizophrenia.
explanation: The study mentions alterations in glutamate (Glu) neurotransmission in schizophrenia, aligning with the statement.
- reference: PMID:37752221
reference_title: "Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex."
supports: SUPPORT
snippet: A subgroup of patients with schizophrenia is believed to have aberrant excess of glutamate in the frontal cortex.
explanation: The study provides evidence of elevated glutamate levels in the frontal cortex in schizophrenia patients.
- reference: PMID:17156977
reference_title: "A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia."
supports: NO_EVIDENCE
snippet: Levels of L-serine, L-glutamine and L-glutamate were unaffected.
explanation: The study reported no significant change in glutamate levels in the brain of schizophrenia patients, contrasting with the statement.
genetic:
- name: DRD2
association: Risk Factor
notes: Dopamine D2 receptor; primary antipsychotic target; GWAS-implicated gene explaining >20% liability in aggregate with other common variants.
- name: GRIN1
association: Risk Factor
notes: NMDA receptor subunit; implicated in glutamatergic dysfunction and cortical disinhibition.
- name: GRIN2A
association: Risk Factor
notes: NMDA receptor subunit; involved in NMDA hypofunction on parvalbumin interneurons.
- name: GAD1
association: Risk Factor
notes: GAD67 enzyme; epigenetically regulated; contributes to GABAergic dysfunction.
- name: RELN
association: Risk Factor
notes: Reelin protein; epigenetically regulated; involved in cortical development and interneuron maturation.
- name: C4A
association: Risk Factor
notes: Complement component 4A; drives excessive microglial synaptic pruning during adolescence.
- name: C3
association: Risk Factor
notes: Complement component 3; works with C4A in complement-mediated synaptic elimination.
- name: DISC1
association: Risk Factor
evidence:
- reference: PMID:30286368
reference_title: "Association on DISC1 SNPs with schizophrenia risk: A meta-analysis."
supports: PARTIAL
snippet: DISC1 gene has been shown as a risk factor for schizophrenia in some reports.
explanation: The meta-analysis confirms associations between specific SNPs in the DISC1 gene and schizophrenia risk.
- reference: PMID:24056909
reference_title: "Questions about DISC1 as a genetic risk factor for schizophrenia."
supports: NO_EVIDENCE
snippet: Questions about DISC1 as a genetic risk factor for schizophrenia.
explanation: This reference raises questions about the role of DISC1 as a risk factor, implying a lack of consensus.
- reference: PMID:30285728
reference_title: "The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions."
supports: PARTIAL
snippet: The human DISC1 gene is located on chromosome 1 and is highly associated with schizophrenia and other mental disorders.
explanation: This study associates the DISC1 gene with schizophrenia among other mental disorders, supporting its role as a risk factor.
- reference: PMID:20302823
reference_title: "Modeling schizophrenia in flies."
supports: NO_EVIDENCE
snippet: Modeling the disease in genetically tractable animals is thus a challenging but increasingly important task. In this review, I discuss the potential problems and perspectives associated with modeling schizophrenia in fruit flies, and briefly review the recent studies analyzing the molecular and cellular functions of Disrupted-In-Schizophrenia-1 (DISC1) in transgenic flies.
explanation: This review highlights the relevance of studying DISC1 functions in the context of schizophrenia.
- name: COMT
association: Risk Factor
evidence:
- reference: PMID:23573605
reference_title: "Schizophrenia, the prefrontal cortex, and a mechanism of genetic susceptibility."
supports: SUPPORT
snippet: 'COMT is an enzyme that is distributed widely throughout the brain, but seems to be uniquely relevant to how dopamine affects information-processing in the prefrontal cortex. There is a common variation in the genetic sequence of the COMT gene, which causes a dramatic change in its enzyme activity. In people with schizophrenia, in their healthy siblings, and also in normal controls, the COMT genotype predicts 4% of the variation in human executive cognition and working memory. We have thus identified a genetic mechanism in the human species that affects the efficiency and efficacy of information-processing in the prefrontal cortex. It is, also, a weak genetic risk factor for schizophrenia: in family studies, it increases the risk of schizophrenia by 50-80%.'
explanation: The COMT gene is identified as a weak genetic risk factor for schizophrenia, increasing the risk by 50-80% in family studies.
- name: NRG1
association: Risk Factor
evidence:
- reference: PMID:16520822
reference_title: "Association of the NRG1 gene and schizophrenia: a meta-analysis."
supports: PARTIAL
snippet: Our meta-analysis provides support for the association of NRG1 with schizophrenia, but indicates that firmly establishing the role of NRG1 gene in schizophrenia by genetic association requires much larger sample sizes than have hitherto been reported.
explanation: The meta-analysis found some evidence supporting the association of NRG1 with schizophrenia, but also highlighted the need for larger sample sizes to firmly establish this role.
- reference: PMID:15162166
reference_title: "Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia."
supports: SUPPORT
snippet: Recently, the gene that encodes neuregulin-1 (NRG1) has been identified as a potential susceptibility gene for schizophrenia, and defects in the expression of erbB3, one of the NRG1 receptors, have been shown to occur in the prefrontal cortex of schizophrenic patients...
explanation: This reference identifies NRG1 as a potential susceptibility gene for schizophrenia, indicating a genetic association.
- reference: PMID:20600464
reference_title: "Genetic findings in schizophrenia patients related to alterations in the intracellular Ca-homeostasis."
supports: SUPPORT
snippet: We mainly focus on genes including:...NRG1 (Neuregulin 1)... Taken together there is converging evidence for the contribution of genes potentially related to alterations in intracellular Ca-homeostasis to the risk of schizophrenia.
explanation: This review points to NRG1 as a gene potentially related to the risk of schizophrenia.
- reference: PMID:24968777
reference_title: "Dopaminergic function in relation to genes associated with risk for schizophrenia: translational mutant mouse models."
supports: SUPPORT
snippet: '...It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1...'
explanation: This paper focuses on NRG1 as one of the risk genes associated with schizophrenia.
- name: DTNBP1
association: Risk Factor
evidence:
- reference: PMID:19862852
reference_title: "Association study of DTNBP1 with schizophrenia in a US sample."
supports: SUPPORT
snippet: This study shows that DTNBP1 is a risk gene for schizophrenia in EAs. Variation at DTNBP1 may modify risk for schizophrenia in this population.
explanation: This reference provides evidence that DTNBP1 is associated with an increased risk of schizophrenia, particularly in European-Americans.
- reference: PMID:18474210
reference_title: "Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature."
supports: SUPPORT
snippet: To date, DTNBP1 has provided the greatest evidence of illness modification, as associations with negative and cognitive symptoms and worse outcome have been published in independent samples.
explanation: This reference elaborates on the association of DTNBP1 with specific clinical features of schizophrenia, further supporting its role as a risk factor.
- reference: PMID:24968777
reference_title: "Dopaminergic function in relation to genes associated with risk for schizophrenia: translational mutant mouse models."
supports: SUPPORT
snippet: It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1, their interactions with environmental factors, and with each other (epistasis).
explanation: This reference discusses the role of DTNBP1 as a risk gene for schizophrenia within the context of genetic and environmental interactions.
environmental:
- name: Prenatal Stress
description: Exposure to stress during fetal development may increase risk.
evidence:
- reference: PMID:33544627
reference_title: "Early Environmental Upheaval and the Risk for Schizophrenia."
supports: SUPPORT
snippet: we appraise the evidence linking schizophrenia spectrum disorder to prenatal maternal stress.
explanation: The review provides evidence linking prenatal stress to the risk of schizophrenia spectrum disorder.
- reference: PMID:26968981
reference_title: "Schizophrenia and reelin: a model based on prenatal stress to study epigenetics, brain development and behavior."
supports: SUPPORT
snippet: prenatal stress induces neurodevelopmental alterations in the prefrontal cortex that are expressed as cognitive impairment observed in schizophrenia.
explanation: The article discusses the association between prenatal stress and neurodevelopmental changes leading to schizophrenia.
- reference: PMID:26753951
reference_title: "Fetal exposure to maternal stress and risk for schizophrenia spectrum disorders among offspring: Differential influences of fetal sex."
supports: SUPPORT
snippet: Findings suggest sex-specific fetal sensitivity to maternal reported daily life stress during pregnancy on risk for SSD, with males appearing to be more vulnerable to the influences of maternal stress during pregnancy.
explanation: The study found that maternal stress during pregnancy is associated with increased risk of schizophrenia spectrum disorders in offspring, particularly males.
- reference: PMID:37116354
reference_title: "A consideration of the increased risk of schizophrenia due to prenatal maternal stress, and the possible role of microglia."
supports: SUPPORT
snippet: Epidemiological findings are rather consistent in supporting the association, albeit they are mitigated by effects of sex and gestational timing.
explanation: The article evaluates evidence linking prenatal maternal stress with an elevated risk of schizophrenia and discusses the role of microglial activation.
- reference: PMID:37783300
reference_title: "Prenatal risk factors and postnatal cannabis exposure: Assessing dual models of schizophrenia-like rodents."
supports: SUPPORT
snippet: Schizophrenia (SCZ) is a multifactorial neurodevelopmental disorder caused by genetic and environmental alterations, especially during prenatal stages.
explanation: The review states that prenatal environmental alterations, including stress, are associated with an increased risk of schizophrenia.
exposure_term:
preferred_term: Prenatal stress exposure
- name: Cannabis Use
description: Associated with increased risk and earlier onset in genetically predisposed individuals.
evidence:
- reference: PMID:24957864
reference_title: "Genetic predisposition to schizophrenia associated with increased use of cannabis."
supports: PARTIAL
snippet: Although considerable evidence implicates cannabis use as a component cause of schizophrenia, it remains unclear whether this is entirely due to cannabis directly raising risk of psychosis, or whether the same genes that increases psychosis risk may also increase risk of cannabis use.
explanation: The study suggests that there is an association between cannabis use and schizophrenia, but it indicates that the genetic components might play a significant role, making it partially supportive.
- reference: PMID:26232243
reference_title: "Environmental factors and the age at onset in first episode psychosis."
supports: SUPPORT
snippet: Individuals with a history of cannabis abuse had an earlier age at onset by nearly six years.
explanation: The study provides direct evidence that cannabis use is associated with an earlier age at onset of psychosis.
- reference: PMID:21068828
reference_title: "The environment and schizophrenia."
supports: SUPPORT
snippet: onset is associated with environmental factors such as early life adversity, growing up in an urban environment, minority group position and cannabis use.
explanation: The association of environmental factors, including cannabis use, supports the idea of increased risk of schizophrenia.
- reference: PMID:28142064
reference_title: "Cannabis use, COMT, BDNF and age at first-episode psychosis."
supports: PARTIAL
snippet: The relationship between age at psychosis onset and COMT Val158Met and BDNF Val66Met polymorphisms with early cannabis use as well as those factors associated with early cannabis use were investigated.
explanation: The study highlights the important role of early cannabis use and genetic polymorphisms in influencing the age at psychosis onset, thereby supporting the statement.
- reference: PMID:37185055
reference_title: "Tobacco use in first-episode psychosis, a multinational EU-GEI study."
supports: PARTIAL
snippet: Tobacco use was associated with an earlier age at psychosis onset...; however, these results were no longer significant after controlling for cannabis use.
explanation: The study indicates that cannabis use correlates with an earlier age at onset of psychosis, supporting the statement.
exposure_term:
preferred_term: Cannabis exposure
term:
id: ECTO:0100005
label: exposure to cannabis
treatments:
- name: Antipsychotic Medications
description: Medications such as risperidone, olanzapine, and clozapine to manage symptoms.
mechanism:
- name: dopamine D2 receptor antagonism
description: Primary action through dopamine D2 receptor antagonism
evidence:
- reference: PMID:12769630
reference_title: "Current status of antipsychotic treatment."
supports: PARTIAL
snippet: With the use of chlorpromazine and other traditional antipsychotics for psychosis, it was soon discovered that the antipsychotic efficacy of this class of medications was closely associated with their ability to block dopamine D(2) receptors in the brain.
explanation: This reference supports the statement that antipsychotic medications act through dopamine D2 receptor antagonism. It also mentions medications like clozapine, risperidone, and others, but does not specifically mention olanzapine in this context.
- reference: PMID:14514482
supports: NO_EVIDENCE
snippet: ''
explanation: The title suggests a focus on schizophrenia treatments, but no abstract provided to verify the contents in relation to the detailed mechanism of action of risperidone, olanzapine, or clozapine.
- reference: PMID:8626371
reference_title: "Management of schizophrenia."
supports: PARTIAL
snippet: The introduction of novel antipsychotic agents, such as clozapine and risperidone, has enhanced the clinicians' ability to manage schizophrenic patients.
explanation: This supports the usage of clozapine and risperidone but does not detail the mechanism focused on dopamine D2 receptor antagonism.
- reference: PMID:15846745
supports: NO_EVIDENCE
snippet: ''
explanation: The reference compares the clinical effects of risperidone and olanzapine, but does not provide information on the mechanism of action through dopamine D2 receptor antagonism.
- reference: PMID:8823348
reference_title: "Treatment-resistant schizophrenic patients."
supports: PARTIAL
snippet: Clozapine has shown to be effective in some poor or partially responsive patients in three prospective, random assignment, double-blind trials.
explanation: Supports effectiveness of clozapine in treatment-resistant patients but does not address dopamine D2 receptor antagonism directly.
- reference: PMID:32464195
reference_title: "Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients."
supports: PARTIAL
snippet: To improve treatment efficacy during the critical early stages of schizophrenia, we aimed to identify molecular signatures at baseline (T0) for prediction of a positive response to the atypical antipsychotics olanzapine and risperidone after 6 weeks (T6) treatment.
explanation: This supports the use of olanzapine and risperidone but does not detail the mechanism involving dopamine D2 receptor antagonism.
- reference: PMID:17845145
reference_title: "Schizophrenia endophenotypes as treatment targets."
supports: PARTIAL
snippet: The drug discovery process has focused mostly on targeting D2 dopamine receptors.
explanation: This reference supports the focus on D2 dopamine receptors in drug discovery, which aligns with the mechanism described.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
- name: Cognitive Behavioral Therapy (CBT)
description: Therapy aimed at changing maladaptive thought patterns and behaviors.
evidence:
- reference: PMID:20880828
reference_title: "Cognitive behavior therapy for schizophrenia and psychosis: current status and future directions."
supports: SUPPORT
snippet: There is good evidence from a considerable number of clinical trials that CBTp has a consistent clinical benefit when used in addition to standard care.
explanation: This indicates that Cognitive Behavioral Therapy (CBT) is a recognized treatment for schizophrenia that aims at changing maladaptive thought patterns and behaviors.
- reference: PMID:27335156
reference_title: "From Clozapine to Cognitive Remediation."
supports: SUPPORT
snippet: Cognitive behavioural therapy for psychosis and cognitive remediation are 2 psychosocial interventions that have demonstrated positive outcomes for violence in SCZ.
explanation: This highlights that CBT, which focuses on changing maladaptive thought patterns and behaviors, is effective in treating certain symptoms of schizophrenia.
- reference: PMID:17716100
reference_title: "Cognitive approaches to schizophrenia: theory and therapy."
supports: PARTIAL
snippet: A theoretical analysis of schizophrenia based on a cognitive model integrates the complex interaction of predisposing neurobiological, environmental, cognitive, and behavioral factors with the diverse symptomatology.
explanation: The statement aligns with the cognitive approach to schizophrenia, which underpins CBT.
- reference: PMID:31699627
reference_title: "Cognitive remediation for schizophrenia: An expert working group white paper on core techniques."
supports: NO_EVIDENCE
snippet: Cognitive remediation is now widely recognized as an effective treatment for cognitive deficits in schizophrenia.
explanation: Although this reference focuses on cognitive remediation, it aligns with the efficacy of cognitive therapies like CBT.
treatment_term:
preferred_term: behavioral counseling
term:
id: MAXO:0000077
label: behavioral counseling
- name: Social Skills Training
description: Programs to enhance social interactions and functioning.
evidence:
- reference: PMID:16885207
reference_title: "Recent advances in social skills training for schizophrenia."
supports: SUPPORT
snippet: Social skills training consists of learning activities utilizing behavioral techniques that enable persons with schizophrenia and other disabling mental disorders to acquire interpersonal disease management and independent living skills for improved functioning in their communities.
explanation: The study states that social skills training helps individuals with schizophrenia to improve functioning in their communities by acquiring interpersonal and independent living skills.
- reference: PMID:31708048
reference_title: "Evidence-Based Psychosocial Treatment for Individuals with Early Psychosis."
supports: SUPPORT
snippet: Common elements to these interventions include building a therapeutic alliance, recovery orientation, education, and skills training, which can be directed to a range of targets, including problem-solving, communication, social skills, and social cognition.
explanation: Clinical therapies for first-episode psychosis as part of coordinated specialty care (CSC) include skills training directed at social skills.
- reference: PMID:23773889
reference_title: "Psychosocial Treatments for Schizophrenia: An Evaluation of Theoretically Divergent Treatment Paradigms, and Their Efficacy."
supports: PARTIAL
snippet: 'METHODOLOGY: Social skills training, cognitive behavioral therapy, cognitive remediation, and social cognitive training therapy paradigms were searched and the extant literature is summarized for each, with particular focus on: 1) the rationale for treatment methodology; 2) particular methods of treatment; and, 3) meta-analytic data regarding their efficacy and/or effectiveness.'
explanation: This reference indicates that social skills training is a recognized psychosocial method used to treat schizophrenia and discusses its efficacy.
- reference: PMID:36050663
reference_title: "Cognitive Enhancement Therapy vs social skills training in schizophrenia: a cluster randomized comparative effectiveness evaluation."
supports: SUPPORT
snippet: Although pharmacological treatments can often lessen the psychotic symptoms that are a hallmark of schizophrenia, they do not lessen the social and cognitive deficits that create the greatest impediments to community engagement and functional recovery.
explanation: The study compares Cognitive Enhancement Therapy and Social Skills Training (HOPES/SST), highlighting their role in improving social and community functioning.
- reference: PMID:32614046
reference_title: "Online Social Cognition Training in Schizophrenia: A Double-Blind, Randomized, Controlled Multi-Site Clinical Trial."
supports: PARTIAL
snippet: To address this need, we have developed SocialVille-an online, plasticity-based training program that targets SC deficits in schizophrenia...These results provide support for the efficacy of a remote, plasticity-based social cognitive training program in improving SC and social functioning in schizophrenia.
explanation: The study shows that social cognitive training programs, which could include elements similar to Social Skills Training, improve social functioning in schizophrenia patients.
- reference: PMID:21860049
reference_title: "Social-cognitive remediation in schizophrenia: generalization of effects of the Training of Affect Recognition (TAR)."
supports: PARTIAL
snippet: Intention-to-treat analyses found significantly larger pre-post improvements with TAR than with CRT in prosodic affect recognition, ToM, and social competence and a trend effect in global social functioning.
explanation: The study indicates that training aimed at social cognition, such as TAR, may improve social skills and functions, relevant to social skills training programs.
treatment_term:
preferred_term: behavioral counseling
term:
id: MAXO:0000077
label: behavioral counseling
- name: Supportive Therapy
description: Ongoing support to help manage daily life and stress.
evidence:
- reference: PMID:15176765
reference_title: "Supportive therapy for schizophrenia: possible mechanisms and implications for adjunctive psychosocial treatments."
supports: SUPPORT
snippet: This article posits that the positive findings for supportive therapy (ST) in recent trials may indicate an important but undervalued aspect of psychosocial interventions for schizophrenia.
explanation: The article discusses the benefits of supportive therapy in schizophrenia treatment and emphasizes mechanisms such as the therapeutic alliance and social support, indicating that ongoing support helps manage daily life and stress.
- reference: PMID:23244011
reference_title: "Supportive psychodynamic psychotherapy versus treatment as usual for first-episode psychosis: two-year outcome."
supports: SUPPORT
snippet: The intervention group improved significantly on measures of both PANSS and GAF scores, with large effect sizes at two years follow-up after inclusion. Further, improvement on GAF(function) (p = 0.000) and GAF(symptom) (p = 0.010) significantly favored SPP in combination with TaU over TaU alone.
explanation: Supportive psychodynamic psychotherapy, a variant of supportive therapy, was found to significantly improve symptoms and functional outcomes, underscoring its role in ongoing support for managing stress and daily life in schizophrenia.
- reference: PMID:31708048
reference_title: "Evidence-Based Psychosocial Treatment for Individuals with Early Psychosis."
supports: SUPPORT
snippet: Group, individual, and family therapies in CSC aim to help the client and family understand and cope with the experience of psychosis, promote symptomatic and functional recovery and improve quality of life, and support the pursuit of personally meaningful goals of the client.
explanation: Coordinated specialty care, including supportive interventions, focuses on coping, recovery, and quality of life, indicating the importance of ongoing support.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
- name: Vocational Rehabilitation
description: Help with gaining and maintaining employment.
evidence:
- reference: PMID:8749891
reference_title: "Vocational rehabilitation in schizophrenia."
supports: PARTIAL
snippet: Most vocational rehabilitation programs have a positive influence on work-related activities, but most have failed to show substantial and enduring impacts on independent, competitive employment.
explanation: While vocational rehabilitation programs have positive influences on work-related activities, they have not generally shown substantial and enduring impacts on competitive employment.
- reference: PMID:31327504
reference_title: "First-episode psychosis and vocational outcomes: A predictive model."
supports: PARTIAL
snippet: At the end of two years in the service, 829 (70.4%) patients were meaningfully employed and 348 (29.6%) patients were unemployed.
explanation: Vocational programs have shown promise with a significant portion of patients being gainfully employed, but it does not necessarily indicate maintaining stable employment over long periods.
- reference: PMID:18715755
reference_title: "Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up."
supports: SUPPORT
snippet: NET training improved vocational outcomes, suggesting the value of combining cognitive remediation with other rehabilitation methods to enhance functional outcomes.
explanation: Neurocognitive enhancement therapy combined with vocational services showed improved employment outcomes, supporting the positive impact on gaining and maintaining employment.
- reference: PMID:32393158
reference_title: "Blending Traditional Vocational Services and Individualized Placement and Support for Formerly Incarcerated Veterans."
supports: SUPPORT
snippet: Veterans in the hybrid condition, compared with the AFVP alone, were more likely to find employment, had higher rates of full-time employment, and earned significantly more money over the course of the study.
explanation: Blended vocational services significantly improved employment outcomes, supporting the effectiveness of vocational rehabilitation in gaining and maintaining employment.
- reference: PMID:29135426
reference_title: "Integrated Supported Employment for People With Schizophrenia in Mainland China: A Randomized Controlled Trial."
supports: SUPPORT
snippet: Significantly higher employment rate and longer job tenure were found in the ISE group (63.0%, 29.56 wk) compared with the IPS group (50.0%, 25.47 wk) and TVR group (33.3%, 9.91 wk).
explanation: Integrated supported employment led to higher employment rates and longer job tenure, indicating that such vocational rehabilitation can help with gaining and maintaining employment.
treatment_term:
preferred_term: occupational therapy
term:
id: MAXO:0001351
label: occupational therapy
disease_term:
preferred_term: schizophrenia
term:
id: MONDO:0005090
label: schizophrenia
classifications:
harrisons_chapter:
- classification_value: psychiatric disorder
Disease Pathophysiology Research Report
Target Disease - Disease Name: Schizophrenia - MONDO ID: MONDO:0005090 - Category: Psychiatric
1) Core Pathophysiology (current understanding) - Polygenic liability and synaptic biology: Schizophrenia is highly polygenic; common variation now explains “more than 20% of the liability” in aggregate, with risk genes enriched in synaptic pathways and including DRD2, consistent with antipsychotic mechanisms (direct quote: “now we can explain more than 20% of the liability to schizophrenia by considering all analyzable common genetic variants,” Molecular Psychiatry, Mar 2023; URL: https://doi.org/10.1038/s41380-023-02005-2) (nakamura2023themolecularpathology pages 16-16). - Dopamine and glutamate interplay with cortical E/I imbalance: Contemporary models integrate mesolimbic hyperdopaminergia (positive symptoms) with cortical NMDA receptor hypofunction on GABAergic/parvalbumin (PV) interneurons, producing disinhibition, excitatory/inhibitory (E/I) imbalance, and downstream dopaminergic dysregulation; ketamine/PCP reproduce psychosis-like states; D-serine (an NMDA co-agonist) and kynurenine/kynurenic acid metabolism abnormalities contribute to NMDA hypofunction (Int J Mol Sci, Oct 2024; URL: https://doi.org/10.3390/ijms251910668) (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 4-5). - Immune–microglial complement signaling and synaptic pruning: Genetic and experimental evidence implicate complement component C4A and microglial CR3 pathways in excessive synaptic elimination, with human and model-system data converging on complement-mediated pruning as a driver of synapse loss (Frontiers in Cellular Neuroscience, Mar 2024; URL: https://doi.org/10.3389/fncel.2024.1345349) (hartmann2024microglianeuroninteractionsin pages 16-16). - Oligodendrocyte/myelin and network dysconnectivity: Myelin/oligodendrocyte abnormalities and white-matter changes are repeatedly observed and conceptually linked to dysconnectivity across brain regions (Antioxidants, Jun 2024; URL: https://doi.org/10.3390/antiox13060709) (rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2). - Mitochondrial–oxidative stress axis: Bioenergetic deficits (e.g., complex I inhibition), decreased glutathione, increased lactate, and inflammatory cytokines support a feed-forward cycle linking mitochondrial dysfunction, oxidative/nitrosative stress, and neuroinflammation; excessive Ca2+ influx via NMDARs can overload mitochondria and trigger cell-death signaling (Antioxidants, Jun 2024; URL: https://doi.org/10.3390/antiox13060709) (rawani2024theunderlyingneurobiological pages 15-16, rawani2024theunderlyingneurobiological pages 4-5). - Neurovascular/BBB dysfunction: Increased BBB permeability (elevated CSF albumin/immunoglobulins) and neurovascular unit abnormalities (endothelial cells, pericytes, astrocytes) are reported and positioned upstream of neurotransmitter dyshomeostasis (Int J Mol Sci, Jan 2024; URL: https://doi.org/10.3390/ijms25021250) (stanca2024thecellulardysfunction pages 1-2).
2) Key Molecular Players - Genes/proteins (HGNC): - DRD2 (dopamine D2 receptor; antipsychotic target; GWAS-implicated) (Molecular Psychiatry, 2023; URL above) (nakamura2023themolecularpathology pages 16-16). - GRIN1/GRIN2A (NMDAR subunits), GAD1 (GAD67), RELN (Reelin) (NMDA/PV interneuron dysfunction and epigenetic regulation discussed) (Int J Mol Sci, 2024; URL above; Antioxidants, 2024; URL above) (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 4-5, rawani2024theunderlyingneurobiological pages 25-26). - C4A (complement component 4A), C3, ITGAM/CD11b (CR3) (microglial complement-mediated synaptic pruning) (Frontiers in Cellular Neuroscience, 2024; URL above) (hartmann2024microglianeuroninteractionsin pages 16-16). - Myelin/oligodendrocyte-associated proteins (conceptual involvement; oligodendroglial/myelination deficits) (Antioxidants, 2024; URL above) (rawani2024theunderlyingneurobiological pages 15-16). - Chemical entities (CHEBI): - Dopamine (CHEBI:18243), glutamate (CHEBI:29985), GABA (CHEBI:16865) (core neurotransmitters) (rawani2024theunderlyingneurobiological pages 4-5, correll2024whatremainsto pages 1-2). - D-serine (CHEBI:17115), kynurenic acid (CHEBI:17368), kynurenine (CHEBI:30785) (NMDAR co-agonist and KP metabolites) (Int J Mol Sci, 2024; URL above) (zhang2024advancesinthe pages 13-14). - Cell types (CL): - PV interneurons (CL:0000099, parvalbumin-positive GABAergic interneurons; NMDA hypofunction/disinhibition) (Int J Mol Sci, 2024; URL above) (zhang2024advancesinthe pages 13-14). - Microglia (CL:0000129; complement-dependent synaptic pruning) (Frontiers in Cellular Neuroscience, 2024) (hartmann2024microglianeuroninteractionsin pages 16-16). - Astrocytes (CL:0000127), endothelial cells (CL:0000115), pericytes (CL:0000669) (neurovascular/BBB) (Int J Mol Sci, 2024; URL above) (stanca2024thecellulardysfunction pages 1-2). - Oligodendrocytes (CL:0000128) (myelin deficits) (Antioxidants, 2024; URL above) (rawani2024theunderlyingneurobiological pages 15-16). - Anatomical locations (UBERON): - Prefrontal cortex (UBERON:0003126), hippocampus (UBERON:0001954), thalamus (UBERON:0001897) (regions linked to cognition and network communication; E/I imbalance, inflammation, and myelin changes) (rawani2024theunderlyingneurobiological pages 4-5, rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2).
3) Biological Processes (GO terms) disrupted - Glutamatergic synaptic transmission and plasticity (GO:0098978; GO:0060291 LTP): NMDA hypofunction, co-agonist deficiency, and KP metabolite modulation (zhang2024advancesinthe pages 13-14). - GABAergic synaptic transmission and interneuron-mediated inhibition (GO:0098982): PV interneuron dysfunction and cortical disinhibition/E/I imbalance (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 4-5). - Dopamine signaling (GO:0007212) and presynaptic modulation by cortical inputs (hyperdopaminergia in mesolimbic circuits) (correll2024whatremainsto pages 1-2, rawani2024theunderlyingneurobiological pages 4-5). - Complement activation and synaptic pruning (GO:0006956; GO:0098883): microglia–CR3–C4/C3 pathways (hartmann2024microglianeuroninteractionsin pages 16-16). - Myelination and axon ensheathment (GO:0042552; GO:0008366): oligodendrocyte disruption and dysconnectivity (rawani2024theunderlyingneurobiological pages 15-16). - Mitochondrial electron transport/oxidative phosphorylation (GO:0006119) and cellular response to oxidative stress (GO:0034599) (rawani2024theunderlyingneurobiological pages 15-16). - Regulation of blood–brain barrier permeability and endothelial junction organization (e.g., GO:0071605, GO:0005911 related components): BBB leakage and neurovascular unit dysfunction (stanca2024thecellulardysfunction pages 1-2).
4) Cellular Components (where key processes occur) - Postsynaptic density (GO:0014069) and glutamatergic synapse (GO:0098978) for NMDA-dependent signaling (zhang2024advancesinthe pages 13-14). - Presynaptic active zone (GO:0048786) and dopaminergic terminals (mesostriatal/mesolimbic) (correll2024whatremainsto pages 1-2). - Microglial phagocytic machinery in perisynaptic microdomains; complement opsonins at synapses (hartmann2024microglianeuroninteractionsin pages 16-16). - Myelin sheath (GO:0043209) and nodes of Ranvier (GO:0033268) for conduction/dysconnectivity (rawani2024theunderlyingneurobiological pages 15-16). - Mitochondrion (GO:0005739) as a hub for redox-bioenergetics and Ca2+-induced injury (rawani2024theunderlyingneurobiological pages 15-16). - Endothelial cell–cell junctions and astrocytic endfeet at BBB (stanca2024thecellulardysfunction pages 1-2).
5) Disease Progression (staged model) - Neurodevelopmental priming: Genetic liability (common and rare) plus early-life immune/inflammatory exposures perturb cortical development, interneuron maturation, and synaptic/myelin programs; polygenic architecture “explains more than 20% of liability” (Molecular Psychiatry, 2023; URL above) (nakamura2023themolecularpathology pages 16-16). Epigenetic alterations impacting NMDARs, GABAergic markers (GAD67), and reelin are noted (Antioxidants, 2024; URL: https://doi.org/10.3390/antiox13060709) (rawani2024theunderlyingneurobiological pages 25-26). - Adolescent critical period: Excessive complement-tagged synaptic pruning by microglia (C4A/C3–CR3) and NMDA hypofunction on PV interneurons drive cortical E/I imbalance; concurrent oligodendrocyte/myelin vulnerability and BBB changes may exacerbate dysconnectivity and neuroinflammation (Frontiers in Cellular Neuroscience, 2024; Int J Mol Sci, 2024; URLs above) (hartmann2024microglianeuroninteractionsin pages 16-16, stanca2024thecellulardysfunction pages 1-2, zhang2024advancesinthe pages 13-14). - Prodrome to first-episode psychosis: Emergence of cognitive/negative symptoms with cortical disinhibition and glutamatergic dysregulation; mesolimbic hyperdopaminergia manifests as positive symptoms (Biomolecules, Jul 2024; URL: https://doi.org/10.3390/biom14080906) (correll2024whatremainsto pages 1-2, rawani2024theunderlyingneurobiological pages 4-5). - Chronic course: Persistent synaptic loss, redox–mitochondrial stress, and myelin/white-matter alterations contribute to refractory negative and cognitive symptoms; ongoing low-grade inflammation and BBB dysfunction may maintain pathophysiology (Antioxidants, 2024; Int J Mol Sci, 2024; URLs above) (rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2).
6) Phenotypic Manifestations (linkage to mechanisms) - Positive symptoms (hallucinations/delusions): Most directly related to striatal/mesolimbic dopamine excess; antipsychotics work as “postsynaptic dopamine antagonists” (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2). - Negative and cognitive symptoms: Associated with cortical NMDA hypofunction and PV interneuron-mediated disinhibition (E/I imbalance) leading to impairments in working memory/executive function; D-serine reduction and KP metabolite elevations (kynurenic acid) are implicated (Int J Mol Sci, Oct 2024; URL above) (zhang2024advancesinthe pages 13-14). “Ketamine/PCP” models reproduce cognitive and negative symptom domains via NMDAR blockade (rawani2024theunderlyingneurobiological pages 4-5). - Functional dysconnectivity: Oligodendrocyte/myelin deficits and inflammation contribute to large-scale network dysconnectivity underlying broad symptom burden (Antioxidants, Jun 2024; URL above) (rawani2024theunderlyingneurobiological pages 15-16).
Applications and Real-World Implementations (biomarkers and therapeutics) - Biomarkers: - CSF/metabolic redox markers: Increased lactate and decreased glutathione have been reported in brain/CSF in schizophrenia, consistent with bioenergetic–oxidative stress (Antioxidants, Jun 2024; URL above) (rawani2024theunderlyingneurobiological pages 15-16). - Neuroinflammatory cytokines (e.g., IL‑6, IL‑8, TNF‑α) are elevated in first-episode and chronic cases (Antioxidants, Jun 2024; URL above) (rawani2024theunderlyingneurobiological pages 4-5). - BBB leakage indices: Elevated CSF albumin/immunoglobulins indicating increased BBB permeability (Int J Mol Sci, Jan 2024; URL above) (stanca2024thecellulardysfunction pages 1-2). - Therapeutic developments: - Dopaminergic antagonism remains the cornerstone for positive symptoms but leaves cognitive/negative symptoms insufficiently treated (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2). - Glutamatergic strategies (e.g., NMDAR co-agonists, glycine transporter or D‑amino acid oxidase inhibitors, mGluR modulators) are being advanced to target cognition and negative symptoms (Int J Mol Sci, Oct 2024; URL above) (zhang2024advancesinthe pages 13-14). - Novel modalities: “Molecular polypharmacy” and biased signaling; KarXT (xanomeline + trospium) exemplifies circuit-/network-minded approaches beyond D2 antagonism (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2).
Relevant Statistics and Data - Prevalence: “approximately 1% of the global population,” emphasizing disability and unmet needs (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2). - Genetics: “now we can explain more than 20% of the liability” from common variants in aggregate; DRD2 is a validated GWAS target reflecting monoaminergic involvement (Molecular Psychiatry, Mar 2023; URL above) (nakamura2023themolecularpathology pages 16-16).
Expert Opinions and Analysis - Therapeutic perspective: Correll et al. emphasize that “schizophrenia’s pathophysiology is not solely reliant on neurotransmitter–receptor interactions,” and promote circuit-level targets, biased agonism, and multi-target strategies to address cognitive/negative symptoms and treatment resistance (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2). - Mechanistic synthesis: Reviews converge that neurotransmission dysregulation (dopamine–glutamate–GABA), neuroinflammation (microglia/complement), redox–mitochondrial stress, and myelin/BBB pathology are interdependent domains that jointly drive clinical heterogeneity (Antioxidants, Jun 2024; URL above; Int J Mol Sci, Jan/Oct 2024; URLs above) (rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2, zhang2024advancesinthe pages 13-14).
Structured Annotations for Knowledge Base - Gene/protein (HGNC): DRD2; GRIN1/GRIN2A; GAD1 (GAD67); RELN; C4A; C3; ITGAM (CR3/CD11b). Evidence: GWAS (DRD2) and mechanistic reviews (complement, NMDA, PV interneuron) (nakamura2023themolecularpathology pages 16-16, zhang2024advancesinthe pages 13-14, hartmann2024microglianeuroninteractionsin pages 16-16). - Biological process (GO): glutamatergic synaptic transmission (GO:0098978); GABAergic synaptic transmission (GO:0098982); complement activation (GO:0006956); synaptic pruning (GO:0098883); myelination (GO:0042552); oxidative phosphorylation (GO:0006119); cellular response to oxidative stress (GO:0034599); regulation of BBB permeability (GO:0071605) (zhang2024advancesinthe pages 13-14, hartmann2024microglianeuroninteractionsin pages 16-16, rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2). - Cellular component (GO): postsynaptic density (GO:0014069); glutamatergic synapse (GO:0098978); myelin sheath (GO:0043209); mitochondrion (GO:0005739); endothelial cell–cell junction (GO:0005911-related) (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2). - Cell types (CL): PV interneurons (CL:0000099); microglia (CL:0000129); astrocytes (CL:0000127); endothelial cells (CL:0000115); oligodendrocytes (CL:0000128) (zhang2024advancesinthe pages 13-14, hartmann2024microglianeuroninteractionsin pages 16-16, stanca2024thecellulardysfunction pages 1-2, rawani2024theunderlyingneurobiological pages 15-16). - Anatomical locations (UBERON): prefrontal cortex (UBERON:0003126); hippocampus (UBERON:0001954); thalamus (UBERON:0001897) (rawani2024theunderlyingneurobiological pages 4-5, rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2). - Phenotype associations (HP): Positive psychotic symptoms (HP:0031464); Negative symptoms (HP:0031466); Cognitive impairment (HP:0100543). Mechanistic links summarized above (zhang2024advancesinthe pages 13-14, correll2024whatremainsto pages 1-2, rawani2024theunderlyingneurobiological pages 4-5). - Chemical entities (CHEBI): dopamine (CHEBI:18243); glutamate (CHEBI:29985); GABA (CHEBI:16865); D-serine (CHEBI:17115); kynurenic acid (CHEBI:17368); kynurenine (CHEBI:30785) (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 4-5).
Directly quoted supporting statements - “now we can explain more than 20% of the liability to schizophrenia by considering all analyzable common genetic variants” (Molecular Psychiatry, Mar 2023; URL: https://doi.org/10.1038/s41380-023-02005-2) (nakamura2023themolecularpathology pages 16-16). - Postsynaptic dopamine antagonists have been “the cornerstone” of treatment, yet “significant challenges remain,” motivating network- and biased-signaling–based approaches (Biomolecules, Jul 2024; URL: https://doi.org/10.3390/biom14080906) (correll2024whatremainsto pages 1-2).
Limitations and gaps - Many biomarker findings (e.g., cytokine panels, redox markers) require replication in large, medication-naïve cohorts. Complement-pruning mechanisms, while strongly supported, still need human in vivo biomarkers to stratify subtypes. Nonetheless, convergent 2023–2024 evidence corroborates multi-domain pathophysiology spanning neurotransmission, immune pruning, myelin/BBB, and redox–mitochondria.
References (URLs and dates) - Nakamura T, Takata A. The molecular pathology of schizophrenia… Molecular Psychiatry, Mar 2023. URL: https://doi.org/10.1038/s41380-023-02005-2 (nakamura2023themolecularpathology pages 16-16). - Zhang T et al. Advances in the treatment of cognitive impairment in schizophrenia: targeting NMDA receptor pathways. Int J Mol Sci, Oct 2024. URL: https://doi.org/10.3390/ijms251910668 (zhang2024advancesinthe pages 13-14). - Correll CU et al. What remains to be discovered in schizophrenia therapeutics… Biomolecules, Jul 2024. URL: https://doi.org/10.3390/biom14080906 (correll2024whatremainsto pages 1-2). - Rawani NS et al. The underlying neurobiological mechanisms of psychosis… Antioxidants, Jun 2024. URL: https://doi.org/10.3390/antiox13060709 (rawani2024theunderlyingneurobiological pages 15-16, rawani2024theunderlyingneurobiological pages 4-5, rawani2024theunderlyingneurobiological pages 25-26). - Stanca S et al. The cellular dysfunction of the brain–blood barrier… Int J Mol Sci, Jan 2024. URL: https://doi.org/10.3390/ijms25021250 (stanca2024thecellulardysfunction pages 1-2). - Hartmann S-M et al. Microglia–neuron interactions in schizophrenia. Frontiers in Cellular Neuroscience, Mar 2024. URL: https://doi.org/10.3389/fncel.2024.1345349 (hartmann2024microglianeuroninteractionsin pages 16-16).
References
(nakamura2023themolecularpathology pages 16-16): Takumi Nakamura and Atsushi Takata. The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research. Molecular Psychiatry, 28:1868-1889, Mar 2023. URL: https://doi.org/10.1038/s41380-023-02005-2, doi:10.1038/s41380-023-02005-2. This article has 51 citations and is from a highest quality peer-reviewed journal.
(zhang2024advancesinthe pages 13-14): Ting Zhang, Chang Liu, Ning Zhong, Yichen Wang, Yiyun Huang, and Xiaoqin Zhang. Advances in the treatment of cognitive impairment in schizophrenia: targeting nmda receptor pathways. International Journal of Molecular Sciences, 25:10668, Oct 2024. URL: https://doi.org/10.3390/ijms251910668, doi:10.3390/ijms251910668. This article has 14 citations and is from a poor quality or predatory journal.
(rawani2024theunderlyingneurobiological pages 4-5): Neha S. Rawani, Allen W. Chan, Serdar M. Dursun, and Glen B. Baker. The underlying neurobiological mechanisms of psychosis: focus on neurotransmission dysregulation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. Antioxidants, 13:709, Jun 2024. URL: https://doi.org/10.3390/antiox13060709, doi:10.3390/antiox13060709. This article has 55 citations and is from a poor quality or predatory journal.
(hartmann2024microglianeuroninteractionsin pages 16-16): Sophia-Marie Hartmann, Johanna Heider, Richard Wüst, Andreas J. Fallgatter, and Hansjürgen Volkmer. Microglia-neuron interactions in schizophrenia. Frontiers in Cellular Neuroscience, Mar 2024. URL: https://doi.org/10.3389/fncel.2024.1345349, doi:10.3389/fncel.2024.1345349. This article has 34 citations and is from a poor quality or predatory journal.
(rawani2024theunderlyingneurobiological pages 15-16): Neha S. Rawani, Allen W. Chan, Serdar M. Dursun, and Glen B. Baker. The underlying neurobiological mechanisms of psychosis: focus on neurotransmission dysregulation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. Antioxidants, 13:709, Jun 2024. URL: https://doi.org/10.3390/antiox13060709, doi:10.3390/antiox13060709. This article has 55 citations and is from a poor quality or predatory journal.
(stanca2024thecellulardysfunction pages 1-2): Stefano Stanca, Martina Rossetti, Leona Bokulic Panichi, and Paolo Bongioanni. The cellular dysfunction of the brain–blood barrier from endothelial cells to astrocytes: the pathway towards neurotransmitter impairment in schizophrenia. International Journal of Molecular Sciences, 25:1250, Jan 2024. URL: https://doi.org/10.3390/ijms25021250, doi:10.3390/ijms25021250. This article has 17 citations and is from a poor quality or predatory journal.
(rawani2024theunderlyingneurobiological pages 25-26): Neha S. Rawani, Allen W. Chan, Serdar M. Dursun, and Glen B. Baker. The underlying neurobiological mechanisms of psychosis: focus on neurotransmission dysregulation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. Antioxidants, 13:709, Jun 2024. URL: https://doi.org/10.3390/antiox13060709, doi:10.3390/antiox13060709. This article has 55 citations and is from a poor quality or predatory journal.
(correll2024whatremainsto pages 1-2): Christoph U. Correll, Massimo Tusconi, Mauro Giovanni Carta, and Serdar M. Dursun. What remains to be discovered in schizophrenia therapeutics: contributions by advancing the molecular mechanisms of drugs for psychosis and schizophrenia. Biomolecules, 14:906, Jul 2024. URL: https://doi.org/10.3390/biom14080906, doi:10.3390/biom14080906. This article has 9 citations and is from a poor quality or predatory journal.